Latham & Watkins Advises Arcus Biosciences in US$250 Million Growth Facility

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, has announced that it has obtained a US$250 million term loan facility from Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in life sciences and technology-related markets. The additional capital strengthens Arcus’ balance sheet and increases flexibility to rapidly advance casdatifan, its potential best-in-class HIF-2a inhibitor.

Latham & Watkins LLP represented Arcus in the transaction with a team led by transactional partners Haim Zaltzman and Mark Roeder, with associates Trevor Church, Erin Cusenbary, and Tyler Davis. Advice was also provided on corporate matters by partner John Williams; on intellectual property matters by partner Jekkie Kim, with associate Mizuna Sekine; on tax matters by partner Eric Cho; on healthcare matters by partner Betty Pang; on FDA/regulatory matters by counsel Chad Jennings; and on other transaction matters by partner Reza Mojtabaee-Zamani, with associate Kevin Zhang.